In the News
WFMZ-TV: Promising Pathways of Blood Biomarkers: Real-World Impact of Bio-Hermes Study, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how blood biomarkers can help identify amyloid plaques, a diagnostic hallmark of Alzheimer’s disease through the Bio-Hermes study. The featured speakers will discuss the impact of this study for those living with the disease as well as physicians and researchers. Attendees will also gain insights into improving Alzheimer’s disease diagnoses […]
Fox 13: Blood test highly effective in determining if memory loss is due to Alzheimer’s disease: Study
By Jordan Bowen, Published July 29, 2024 10:22pm EDT Could a blood test help diagnose Alzheimer’s? A study published in the Journal of the American Medical Association found a specific blood test known as the p-tau217 can determine if someone’s memory loss issues are caused by Alzheimer’s disease. TAMPA, Fla. – It’s a fear many of us have […]
UNLV and Innovative Clinical Research Organization Collaborating to Bring Next Generation Research to Las Vegas
Partnership to Cultivate Best-In Class Clinical Research Services for Alzheimer’s disease and related dementias Washington D.C. – July 12, 2024 – Today, Global Alzheimer’s Platform Foundation® (GAP) and the University of Nevada, Las Vegas (UNLV), announced a memorandum of understanding (MOU) regarding a collaboration to accelerate research for neurodegenerative diseases. This includes establishing a state-of-the-art […]
AP News: Cumulus Neuroscience to Join Bio-Hermes 2 Study with Funding from the Innovate UK Small Business Research Initiative (SBRI) Dementia Mission Project
Funded by a nearly £1.2M (~$1.5M USD) award, this research will enable ongoing validation of AccelADx™, a breakthrough screening test for early detection of Alzheimer’s dementia. BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through […]
PharmiWeb: Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes 2 project
Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes 2 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK. The Bio-Hermes 2 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine […]
UK Research and Innovation: UK and US join forces to tackle dementia with innovative biomarkers
10 July 2024 Innovate UK has awarded four UK companies a share of £4 million funding through Contracts for Innovation to support innovative research into dementia diagnosis. The funding will enable organisations to evaluate blood-based and digital biomarkers as part of the Bio-Hermes-002 study. This international study is led by the Global Alzheimer’s Platform Foundation® […]
Dementia Mission Competition Selects Four Companies For Innovative Alzheimer’s Biomarker Study
Collaboration with Innovate UK Yields New Partners for Alzheimer’s Study Washington D.C., July 10, 2024- With groundbreaking creativity and breathtaking speed, this phase 3 competition, funded by Innovate UK, the UK’s innovation agency, is supporting organizations committed to improving dementia research using blood-based and digital biomarkers. This competition received 14 proposals within one week, from […]
Gwinnett Daily Post: Global Alzheimer’s Platform Foundation Appoints Snellville Resident Director of Recruitment And Strategic Initiatives
The Washington, D.C.-based Global Alzheimer’s Platform Foundation announced on July 8 that Snellville resident Tamiko MaGee-Rodgers has been named director of the foundation’s Recruitment and Strategic Initiatives. The nonprofit GAP was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research and lowering the cost and duration of […]
Global Alzheimer’s Platform Foundation Names Chief Impact Officer and Director of Recruitment & Strategic Initiatives Among Promotions
Washington D.C., July 8, 2024- Global Alzheimer’s Platform Foundation® (GAP) announced the appointment of Leigh Zisko, MPH as Chief Impact Officer and Tamiko MaGee-Rodgers, PhD, CCRP as the Director of Recruitment and Strategic Initiatives. In newly created global leadership roles, each will meaningfully contribute new perspectives and experience to GAP’s work in innovating clinical trial […]
Global Alzheimer’s Platform Foundation: Full FDA Approval of Donanemab Signifies Brighter Future
Washington D.C., July 2, 2024- Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer applauds the U.S. Food and Drug Administration (FDA) for its decision granting full traditional approval of Eli Lilly and Company’s Kisunla™ (donanemab), a disease-modifying Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease (AD). “Today, the FDA grants full approval for donanemab, […]